OBJECTIVE	The aim of the present study was to determine the relative bioavailability and safety profile of a single dose of gefitinib , an orally active inhibitor of epidermal growth factor receptor tyrosine kinase , when administered as a whole 250-mg tablet or as a dispersion preparation via drink or nasogastric tube in healthy male volunteers .\